Ab­b­Vie and Al­pha­bet's Cal­i­co added to Op­er­a­tion Warp Speed for rare dis­eases

12 months ago
R&D

Neu­ro­science com­pa­ny Rap­port Ther­a­peu­tics lists on Nas­daq

12 months ago
R&D

Ali­gos, Ar­bu­tus and oth­ers tout ear­ly he­pati­tis ef­fi­ca­cy da­ta at #EASL24

12 months ago
R&D

Ipsen re­turns to Maren­go Ther­a­peu­tics for new trispe­cif­ic deal

12 months ago
Deals
R&D

Boehringer In­gel­heim, Zealand tout key fi­bro­sis da­ta from mid-stage MASH tri­al

12 months ago
R&D

Bio­mea’s ear­ly-stage di­a­betes drug put on full clin­i­cal hold, stock crash­es

12 months ago
R&D

Google's par­ent com­pa­ny Al­pha­bet poach­es Eli Lil­ly CFO; More changes at Ex­sci­en­tia

12 months ago
People
Peer Review

Sen­ate fails to pass bill cod­i­fy­ing ac­cess to con­tra­cep­tion

Last year
Pharma
FDA+

FDA ex­plains why it re­ject­ed Van­da's in­som­nia ap­pli­ca­tion as com­pa­ny faces takeover bid

Last year
Pharma
FDA+

Safe­ty, ef­fi­ca­cy and dos­ing ques­tions linger for Lil­ly's Alzheimer's drug ahead of Mon­day ad­comm

Last year
Pharma
FDA+

Nine years and four gener­ics lat­er, the HIV drug at the cen­ter of the Shkre­li con­tro­ver­sy still has a high price

Last year
Pharma

Ab­b­Vie gets first taste of Ela­here po­ten­tial with new mid-stage win

Last year
R&D
Pharma

J&J’s deal­mak­er: Plen­ty of ‘fire­pow­er,’ but most­ly fo­cused on tuck-in M&A

Last year
Deals
Pharma

Mer­ck KGaA’s South Ko­re­an part­ner­ship; Sanofi’s sup­ply chain al­liance with DHL

Last year
Manufacturing

Replimune aims for ac­cel­er­at­ed ap­proval of melanoma ther­a­py; Struc­ture's up­sized $476M of­fer­ing

Last year
News Briefing

Ex­clu­sive: Wal­mart shut down its health­care clin­ics af­ter loss­es reached near­ly a quar­ter of a bil­lion dol­lars

Last year
Health Tech

GSK ac­quires tiny RNA start­up Elsie, boost­ing its grand plans for de­vel­op­ing RNA drugs

Last year
Deals

Boehringer In­gel­heim, Zealand’s pos­i­tive Phase 2 MASH fi­bro­sis da­ta ‘un­in­ten­tion­al­ly’ re­leased

Last year
R&D

Mod­er­na’s mR­NA can­di­date picked for FDA’s Op­er­a­tion Warp Speed for rare dis­eases

Last year
R&D

To pay off debt and stay open, Seres will sell mi­cro­bio­me pill to part­ner Nestlé

Last year
Deals

Who are the women mak­ing a mark in bio­phar­ma R&D? Nom­i­nate them for End­points’ 2024 spe­cial re­port

Last year
Special

Vir­tu­al phys­i­cal ther­a­py pro­grams can be just as good as in-per­son care, re­port says

Last year
Startups
Health Tech

Ger­man ra­dio­phar­ma nabs €188M to boost iso­tope man­u­fac­tur­ing, ad­vance can­cer pipeline

Last year
Financing
Manufacturing

For­mer Sanofi R&D leader Frank Nes­tle to lead Deer­field’s grow­ing drug dis­cov­ery arm

Last year
People
R&D
First page Previous page 146147148149150151152 Next page Last page
A service from the Financial Times